Status:
RECRUITING
Study on Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Advanced Parkinson's Disease
Lead Sponsor:
AbbVie
Conditions:
Parkinson's Disease
Eligibility:
All Genders
18+ years
Brief Summary
Main objective of this study is to describe the evolution of infusion settings (base, high and low infusion rates) of foslevodopa/foscarbidopa subcutaneous infusion (LDp/CDp) at different timepoints i...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- \- Diagnosed with levodopa-responsive idiopathic Parkinson's Disease prescribed on LDp/CDp CSCI in routine clinical practice who have consented to be enrolled in the AbbVie Patient Support Program.
Exclusion
Key Trial Info
Start Date :
April 14 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT06937034
Start Date
April 14 2025
End Date
December 1 2025
Last Update
August 5 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Medizinische Universitaet Graz /ID# 278569
Graz, Styria, Austria, 8010
2
Medisch Spectrum Twente /ID# 276695
Enschede, Overijssel, Netherlands, 7512 KZ
3
Universitatea De Medicină Și Farmacie Victor Babeș /ID# 276720
Timișoara, Timiș County, Romania, 300041
4
Karolinska University Hospital Solna /ID# 277116
Solna, Stockholm County, Sweden, 171 64